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37 1. Different ssRNA and dsRNA can be produced in vitro using bacteriophage T7 
38 DNA-dependent RNA polymerase and phi6 RNA-dependent RNA polymerase, 
39 respectively. 
40 2. RNA can be delivered into cells by various transfection methods, however, the 
41 timing, amount, purification and the reagents for RNA transfection should be 
42 carefully considered.
43 3. Produced ssRNA and dsRNA can be applied e.g. in studying host innate immune 
44 responses, demonstrating that RIG-I preferentially recognizes short 
45 dsRNAs/ssRNAs bearing 5’end triphosphate group, while MDA5 recognizes 
46 longer dsRNA molecules. 
47 4. This in vitro RNA synthesis system can produce DsiRNA swarms with basically 
48 any virus (or microbe) specificity for protecting host cells from virus infection.
4
49 Summary (words 238)
50 Mammalian cells express different types of RNA molecules that can be classified as 
51 protein coding RNAs (mRNA) and non-coding RNAs (ncRNAs) the latter of which 
52 have housekeeping and regulatory functions in cells. Cellular RNAs are not 
53 recognized by cellular pattern recognition receptors (PRRs) and innate immunity is 
54 not activated. RNA viruses encode and express RNA molecules that usually differ 
55 from cell-specific RNAs and they include for instance 5’capped and 5’mono- and 
56 triphosphorylated RNAs, small viral RNAs and viral RNA-protein complexes called 
57 vRNPs. These molecules are recognized by certain members of Toll-like receptor 
58 (TLR) and RIG-I-like receptor (RLR) families leading to activation of innate immune 
59 responses and the production of antiviral cytokines, such as type I and type III 
60 interferons (IFNs). Virus-specific ssRNA and dsRNA molecules that mimic the viral 
61 genomic RNAs or their replication intermediates can efficiently be produced by 
62 bacteriophage T7 DNA-dependent RNA polymerase and bacteriophage phi6 
63 RNA-dependent RNA polymerase, respectively. These molecules can then be 
64 delivered into mammalian cells and the mechanisms of activation of innate immune 
65 responses can be studied. In addition, synthetic viral dsRNAs can be processed to 
66 small interfering RNAs (siRNAs) by a Dicer enzyme to produce a swarm of antiviral 
67 siRNAs. Here we describe the biology of RNAs, their in vitro production and delivery 
68 into mammalian cells as well as how these molecules can be used to inhibit virus 




72 Ribonucleic acids (RNAs) are versatile macromolecules which exist in many different 
73 sizes and forms and they possess various essential biological functions. The 
74 fundamental function of RNAs is to mediate genetic information from DNA to 
75 proteins as well as to regulate important steps in the cellular life cycle. In the 1950s 
76 and 1960s, RNA was first known to participate in protein biosynthesis and three types 
77 of RNAs in eukaryotic cells were found, messenger RNA (mRNA), ribosomal RNA 
78 (rRNA) and transfer RNA (tRNA) [1-4]. During the following six or seven decades, 
79 additional RNA types and their different forms and modifications were identified. It is 
80 evident that different types of housekeeping and regulatory RNA molecules have 
81 essential and complicated functions in the life cycle of cells and whole organisms. 
82 RNA viruses express various types of RNA molecules which are often structurally 
83 different from host RNAs and they are thus recognized as foreign structures by 
84 different cellular receptors, which leads to the activation of host innate immune 
85 responses.
86
87 2. RNA classification
88 Endogenous RNAs can be classified into two groups: coding RNAs and non-coding 
89 RNAs (ncRNAs) (Fig. 1). Coding RNAs, also known as mRNAs are transcribed from 
90 DNA and they are translated into polymers of amino acids to form proteins. In 
91 eukaryotic cells gene transcription leads to the production of precursor mRNAs 
92 (pre-mRNAs) which are further processed into mature mRNAs via extensive RNA 
6
93 processing steps (splicing). NcRNAs are not translated into proteins. However, there 
94 are many types of ncRNAs which play different vital roles during the cellular life 
95 cycle. For example, as housekeeping ncRNAs, rRNAs are the key components of 
96 ribosomes, the protein synthesis machinery of the cell [5-7]; tRNAs participate in 
97 mRNA translation by carrying amino acids to ribosomes and by acting as adaptor and 
98 decoder molecules to translate the codon sequence of mRNA to amino acid sequence 
99 in proteins [8-10]; small nuclear RNA (snRNA) and small nucleolar RNA (snoRNA) 
100 molecules, found in the nucleus of eukaryotic cells, are involved in post- 
101 transcriptional modification of RNAs [11]; snRNA is responsible for alternative 
102 splicing of pre-mRNA molecules to define sequences to be translated [12]; and 
103 snoRNA is involved in rRNA and tRNA modification, mRNA editing and genome 
104 imprinting [13]. Moreover, there are several regulatory ncRNAs which can be divided 
105 into long ncRNAs and short ncRNAs according to the length of RNAs. Long ncRNAs 
106 include e.g. circular intronic and circular RNAs (ciRNA, circRNA), long intergenic 
107 ncRNA (lincRNA), and pseudogene transcripts. They act as important regulators of 
108 diverse biological processes [14-16]. Short ncRNAs are comprised of microRNAs 
109 (miRNA) [17], piwi-interacting RNAs (piRNA) [18] and small interfering RNAs 
110 (siRNA) [19], which are involved in RNA silencing and post-transcriptional 
111 regulation of gene expression via different mechanisms and pathways [20]. In order to 
112 prevent cellular RNA from 5’ to 3’ exonuclease cleavage and triggering innate 
113 immune responses, the 5’end of endogenous RNAs are usually protected by various 
114 structural elements. For instance, the 5’end of mRNA is blocked by a cap structure - a 
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115 5’-5’ linked N7-methyl guanosine (m7G) cap to the first nucleotide of the RNA [21]. 
116 The protection of non-coding RNAs is normally achieved by forming a 
117 ribonucleoparticle with its associated proteins which shield 5’ end of RNAs [22]. 
118 Moreover, some lncRNAs such as circRNAs do not harbor open 5’ and 3’ ends since 
119 they form a ring structure and link the 3’ and 5’ ends with a back splicing covalent 
120 bond [23].         
121 Beside endogenous RNAs, different types of foreign RNAs can be released while 
122 cells are invaded by various pathogens such as viruses (Fig. 1) [24]. These RNAs 
123 include viral genomic ssRNAs and dsRNAs, RNA replication intermediates with 
124 different 5’end groups, small viral RNAs generated during infection [25], and special 
125 RNA-protein complexes, such as vRNPs formed during influenza virus infection [26]. 
126 Unlike in endogenous RNAs, the 5’end structure of most foreign RNA molecules are 
127 often exposed. Viral genomic ssRNAs, dsRNA intermediates and some small aberrant 
128 viral RNA transcripts bearing 5’end triphosphate groups can be recognized by a group 
129 of microbial sensors called pattern recognition receptors (PPRs), which then trigger 
130 innate immune responses by activating multiple host cell signaling pathways [27]. 
131 Disturbances in this surveillance system may lead to inflammatory or autoimmune 
132 diseases. Although the host has intricate recognition systems to discriminate between 
133 microbial and endogenous RNAs [28], misprocessed, or mislocalized host-derived 
134 RNAs generated during virus infection can also be recognized by PRRs, such as 
135 Retinoic acid-inducible gene I (RIG-I)–like receptors (RLRs) and Toll-like receptors 
136 (TLRs), leading to activation of abnormal innate immune responses [29]. However, 
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137 during the evolution some viruses have developed various mechanisms to modify 
138 their genomic and mRNA 5' ends. Such structures include e.g. an RNA cap which 
139 addition is catalyzed by specific viral capping enzymes or is obtained by 
140 cap-snatching, i.e. by stealing the cap from host mRNA [21]. Many ssRNA viruses 
141 also have a short protein tag, known as viral protein genome-linked or VPg, 
142 covalently bond to the 5’end of the genomic ssRNA. Alternatively, viruses may shield 
143 the 5’end of RNA via non-covalent interactions with proteins as in vRNP viral 
144 polymerase complex structure [26] or by enclosing the viral RNA in protein or lipid 
145 compartments which protect the RNA. These mechanisms allow efficient 
146 transcription of viral RNAs, avoiding viral RNA degradation by cellular 5'–3' 
147 exonucleases, and circumventing the viral RNA recognition by the host cell. 
148
149 3. In vitro production methods for RNA molecules
150 During the past decades RNA-related research has made significant progress and the 
151 demand for different RNAs has increased. The development of methods to produce 
152 different types of RNAs or RNA mimics in vitro has been essential for various fields 
153 of research contributing to our understanding on the role of various cellular RNAs, the 
154 recognition of invading pathogenic RNAs, and RNA-induced activation of host innate 
155 immune responses. Besides synthesizing polyinosine–polycytidylic acid (poly I:C) as 
156 a dsRNA analog [30], presently two main approaches are used to produce RNAs in 
157 vitro: chemical synthesis and enzymatic production. The chemical synthesis method 
158 for RNA production is normally implemented as an automated solid-phase synthesis 
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159 from ribonucleoside phosphoramidite substrates [31]. However, the need to protect 
160 the 2’-hydroxyl group of the substrate molecules during the chemical synthesis of 
161 RNA creates steric hindrance which greatly reduces the coupling efficiency of RNA 
162 phosphoramidite monomers and thus the RNA yields [32]. Moreover, this approach 
163 mainly generates ssRNA molecules and for the production of dsRNAs there is a need 
164 to hybridize the cognate ssRNAs. The chemical synthesis method has also other 
165 limitations: the method is relatively inaccurate in producing RNA molecules with a 
166 correct length and sequence. It is also expensive which restricts its industrial or 
167 clinical application possibilities, and the size-range of produced RNA is small, 
168 typically less than 100 nucleotides, while naturally expressed, biologically active 
169 RNAs are generally substantially longer [33].   
170 The classical way of enzymatic RNA generation is in vitro transcription of 
171 target DNA sequence containing the T7 polymerase promoter utilizing T7 
172 DNA-dependent RNA polymerase (DdRp) [34]. With this method long ssRNA 
173 molecules with basically any sequence specificity can be produced, which is a clear 
174 benefit compared to chemical synthesis of short RNAs. However, in order to produce 
175 dsRNAs, DNA templates in both sense and antisense orientation should be designed 
176 and the produced ssRNA transcripts must be hybridized after in vitro production. The 
177 accuracy of hybridization is often compromised, especially in the case of long ssRNA 
178 molecules, due to the formation of ssRNA secondary structures by self-annealing or 
179 false-annealing between the strands. Therefore, the yield of produced dsRNA is often 
180 limited since many mis-annealed dsRNA or biologically inactive dsRNA molecules 
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181 are generated during the annealing step.
182 In order to avoid the defects and limitations of the traditional dsRNA production 
183 methods, our laboratory has introduced an enzymatic dsRNA synthesis platform, 
184 making the enzymatic production of different size and type of RNAs possible (Fig. 2, 
185 Supplementary Material). DNA target sequences are first designed according to the 
186 application of desired RNA products, and ssRNAs with different lengths (short, 
187 medium size or long) are in vitro transcribed by T7 DdRp. Unlike in the classical 
188 dsRNA production method, different dsRNAs can be directly synthesized from the 
189 produced ssRNA templates by bacteriophage phi6 RNA-dependent RNA polymerase 
190 (RdRp) [35]. The phi6 RdRp is produced as a recombinant protein, purified to 
191 homogeneity and used for in vitro synthesis of dsRNA. The enzyme has high 
192 processivity and low template specificity which enables efficient production of 
193 dsRNAs from a wide variety of heterologous ssRNA templates [35,36]. The generated 
194 ssRNAs or dsRNAs can subsequently be further modified, e.g. by dephosphorylation 
195 or capping, depending on the needs of further applications [37]. Generated ssRNAs 
196 and dsRNAs can be then precipitated by LiCl or ethanol precipitation, or be obtained 
197 by Trisol extraction method, and be desalted by a NAP column system and further 
198 purified by HPLC purification before their use in various chemical or biological 
199 processes [37].
200 Moreover, the developed RNA synthesis platform also allows us to produce a 
201 target-specific siRNA swarm to be used as antiviral substances against viral infections 
202 which may provide an efficient and potential novel method for inhibiting emerging 
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203 viral infection outbreaks (Fig. 2, Supplementary Material). Designed target DNA 
204 sequences can be used to directly generate desired dsRNAs in a single-tube process 
205 combining T7 DdRp catalyzed ssRNA transcription and phi6 RdRp-based dsRNA 
206 synthesis. DsRNAs can then be further digested by Giardia intestinalis or human 
207 Dicer enzymes to generate the swarms of Dicer-substrate siRNA (DsiRNA) [39,42], 
208 followed by purification through anion-exchange chromatography on a monolithic 
209 QA column [38,39] or GEN-PAK FAX column (Supplementary Material and [36]) 
210 and NAP column desalting [38,39]. DsiRNA swarms generated in vitro can target 
211 multiple viral genomic sequences and mRNAs so that infection of viruses even with 
212 high genetic variation (e.g. influenza virus, hepatitis C virus, human 
213 immunodeficiency virus) can be efficiently inhibited by the DsiRNA swarm as 
214 compared to a single-target siRNA approach [40]. Moreover, low concentration of 
215 each individual siRNA type in the swarm reduces the possibility of severe off-target 
216 effects [41]. Indeed, several studies have demonstrated that DsiRNA swarms 
217 generated with this novel method can efficiently inhibit both DNA and RNA virus 
218 infections without inducing detectable off-target effects [36,39,42-45].
219 For example, our recent research [42] showed that an in vitro synthesized 
220 influenza A virus-specific siRNA  efficiently inhibits the replication of several 
221 influenza A virus strains in human primary cells (Fig. 3), confirming that a swarm of 
222 virus-specific siRNA can act as a broad-spectrum inhibitor.
223 4. RNA delivery methods
224 During the past decades, researchers have been trying to overcome one of the major 
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225 challenges for utilizing in vitro synthesized RNAs in basic and applied research – the 
226 efficacy of intracellular delivery of RNA. RNAs, especially ssRNAs, are prone to 
227 degradation by endogenous RNA-degrading enzymes. Moreover, due to their 
228 relatively large molecular size and strong negative charge, RNAs cannot readily cross 
229 negatively charged cellular membranes [46]. Proper RNA delivery methods are 
230 required to improve RNA entry into the cells and to avoid endosomal uptake in order 
231 to get RNAs transported directly into the cell cytoplasm [47]. Currently, various 
232 means of RNA delivery have been developed. Generally, RNA delivery can be 
233 mediated by viral and non-viral carriers. Adenoviruses [48], adeno-associated viruses 
234 [49], lentiviruses [50,51] and retroviruses [52] are commonly used viral carriers for 
235 RNA delivery. However, all these viral carriers are mainly used for the delivery of 
236 short RNA molecules, such as siRNAs and short hairpin RNAs (shRNAs) [53]. 
237 Although these vectors are suitable for the delivery of siRNAs into almost all types of 
238 cells, and can be applied into in vivo studies due to their very high transduction 
239 efficacy and long-term silencing efficacy, their applicability is still limited due to 
240 concerns in biosafety, such as risks of high immunogenicity and potential insertional 
241 mutagenesis associated with the application of viral vector in RNA delivery [53]. To 
242 circumvent safety concerns and other limitations of viral vectors, non-viral delivery 
243 systems, which comprise cationic polymers and lipids, have been extensively 
244 developed as well [54]. Although these carriers have lower efficiency as compared to 
245 their viral counterparts, they are easy to produce and safer to use, and they provide the 
246 possibility to deliver a broader range of RNA types. As nanoparticle-based delivery 
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247 vehicles, lipid-based carriers and natural polymers including chitosan, atelocollagen, 
248 cationic polypeptides, and synthetic polymers, such as linear and branched 
249 polyethyleneimine (PEI), polyL-lysine (PLL), linear polyamido amines (PAA) and 
250 polyamido amine dendrimers (PAMAM), have been widely used for RNA delivery 
251 [55]. Of these, the lipid-based carriers are the most studied ones and commonly used 
252 for intracellular RNA delivery [56]. Cationic lipids can form bilayers due to their 
253 amphipathic properties and they can electrostatically bind negatively charged RNA 
254 molecules to form lipid-RNA complexes which have the natural capacity to merge 
255 with cellular membranes to mediate RNA uptake into cells [53,54,57]. However, we 
256 know that some types of cells, such as human primary cells, are difficult to transfect. 
257 Therefore, novel transfection methods and reagents are urgently required. Currently, 
258 several novel transfection methods have been developed and used for RNA delivery, 
259 including electroporation, sonoporation and magnetofection. Electroporation is a 
260 physical transfection method which creates temporarily small pores in cell membranes 
261 by applying an electrical field to increase the permeability of cell membranes to 
262 facilitate the entry of RNAs into cells [58]. This technique has very high transfection 
263 efficiency and has been widely applied in the transfection of all kinds of cells 
264 including human primary cells such as human dendritic cells and neurons [59,60]. 
265 Similar to electroporation where RNA is driven into cells by an electrical force along 
266 the electric field, sonoporation is a transfection method using ultrasound to form small 
267 pores in cell membranes leading to transfer of RNA into the cells [61]. In 
268 sonoporation RNA delivery is mediated by passive diffusion and the method is less 
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269 toxic than RNA transfection methods with viral carriers. However, the efficiency 
270 depends on ultrasound frequency and intensity, and similar to electroporation, it may 
271 damage target cells. Magnetofection is a simple and highly efficient transfection 
272 method which utilizes metallic nanoparticles coated with cationic molecules to form 
273 complexes with nucleic acids by electrostatic and hydrophobic interactions [62]. The 
274 particles containing RNAs are then concentrated and transported into the target cells 
275 by an appropriate magnetic field. This method combines the advantages of 
276 biochemical and physical transfection methods reducing the disadvantages of single 
277 methods (low efficiency, high toxicity). Magnetofection enables cells to be RNA 
278 transfected without physically damaging the cells.
279    
280 5. RNA application in the research of innate immunity
281 Recent years have witnessed an explosion in interest and research in innate immunity. 
282 Pathogen recognition by PRRs is an early and essential step in triggering the innate 
283 immune system [24]. How PRRs recognize different pathogen-associated molecular 
284 patterns (PAMPs) and how they discriminate self from foreign RNA molecules [27,28] 
285 are currently extensively studied questions in the field. Detailed analyses of such 
286 phenomena rely on the use of specifically designed RNA mimics. With our versatile 
287 RNA synthesis platform, we can generate various types of pathogen-specific RNA 
288 mimics, such as mimics of short or long viral ssRNA or dsRNA molecules generated 
289 during virus infection, viral genomic RNAs with 5’end triphosphate groups, and 
290 mimics of self RNAs with 5’end cap structure (Fig. 2). These RNA molecules can be 
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291 applied to stimulate different types of host cells or experimental animal models in 
292 order to better study the mechanisms of activation of the innate immune system. The 
293 potential of siRNAs as antiviral substances can also be studied [36,39,42-45].
294 As the sentinel cell of the host, the human dendritic cell (DC) is one of the key 
295 cell types regulating innate and adaptive immunity. It functions as a major 
296 antigen-presenting cell linking innate and adaptive immune systems [63,64]. Several 
297 PRRs are expressed in DCs which recognize different PAMPs upon the invasion of 
298 microbial pathogens [65]. Innate immune responses in early stages of infection in 
299 DCs can be specifically studied using PAMP mimics, such as different types of in 
300 vitro-produced RNA molecules. However, as primary cells, DCs are very fragile upon 
301 stimulation and efficient delivery of RNAs into the cells is demanding. We compared 
302 the RNA transfection efficiency of several commercially available transfection 
303 reagents in DCs and analyzed their effects on cell viability. Although most of the 
304 transfection reagents possessed relatively high RNA transfection efficiency, some of 
305 them led to increased cell death, especially when used with high amounts of RNA 
306 (Fig. 4). Moreover, according to our previous study, transfection of siRNAs against 
307 influenza A virus should take place before virus infection in order to get host cells 
308 well protected against the infection [42]. It is noteworthy that all in vitro 
309 enzymatically produced RNAs should be purified by a NAP column desalting and 
310 anion-exchange HPLC before RNA delivery, otherwise the stability and transfection 
311 efficacy of transfected RNAs and the cell viability after RNA delivery will be 
312 dramatically reduced. Therefore, the timing, amount, purification and the reagents for 
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313 RNA transfection should be carefully chosen. 
314 Several PRRs, which reside in host cells, recognize different types of foreign 
315 RNAs and trigger the induction of type I and III interferons (IFNs) through multiple 
316 intracellular signaling pathways [66,67]. RNA-recognizing PRRs include RLRs and 
317 TLRs. RLRs reside in the cell cytoplasm, such as the RIG-I molecule which mainly 
318 recognizes short RNAs bearing a 5’end triphosphate group, and melanoma 
319 differentiation-associated gene 5 (MDA5) which preferentially recognizes long 
320 dsRNAs [68]. In humans, the TLR family includes altogether 10 members of which 
321 TLR3, TLR7 and TLR8 are RNA-recognizing receptors. These TLR molecules are 
322 expressed on the plasma membrane (TLR3) or in endosomes and the endoplasmic 
323 reticulum (TLR3, TLR7 and TLR8) [69]. Currently, chemically synthesized RNAs or 
324 RNA analogues are the most used agonists to study RNA recognition by RLRs or 
325 TLRs [69-75]. Initially Dr. Kato and his colleague identified the length-dependent 
326 recognition by RIG-I and MDA5 by using different-size poly I:C as an RNA agonist 
327 [76,77]. Poly I:C is synthesized by annealing different size single-stranded inosine 
328 poly(I) and cytidine poly(C) homopolymers resulting in a mixture of dsRNA 
329 analogues which have a wide size range (such as low and high molecular weight poly 
330 I:C in size ranges of 0.2kb-1kb and 1.5kb-8kb, respectively). In addition to the size 
331 distribution, poly I:C lacks any sequence specificity for microbial (viral) genomes or 
332 RNAs. Furthermore, homopolymeric sequences do not exist in nature and inosine is a 
333 minor component in natural RNAs, questioning the relevance of poly I:C as an RNA 
334 mimic. With our enzymatic RNA production platform, we can synthesize ssRNAs and 
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335 dsRNAs (short, medium size and long RNAs) ranging from 58bp up to 3kb [37] with 
336 substantially higher sequence accuracy than by using chemical synthesis from any 
337 microbial sequence. Previous studies using poly I:C suggested that RIG-I 
338 preferentially recognizes RNA molecules of less than 1kb and MDA5 recognizes 
339 dsRNA molecules larger than 1kb [76]. Our result from RIG-I and MDA5 knock-out 
340 (KO) and RIG-I/MDA5 double KO cells stimulated with enzymatically produced 
341 dsRNAs showed that RIG-I can still recognize 1.8 kb-long dsRNAs and MDA5 can 
342 recognize as short as 300 bp long dsRNAs (Fig. 5). By using in vitro-produced, 
343 different size, sequence and modification-specific RNAs we can get more detailed 
344 information e.g. of the length-dependent recognition by RLRs. Moreover, by 
345 stimulating human primary macrophages and DCs with in vitro enzymatically 
346 synthesized ssRNAs or dsRNAs with different length and different 5’end group, we 
347 noticed that RIG-I plays a dominant role in recognizing foreign, non-host-specific 
348 RNAs in human primary cells [37]. So with the novel in vitro RNA synthesis method, 
349 we can obtain a versatile collection of RNA mimics in order to study in more detail 
350 what type of RNAs are recognized by different PRRs. We can also further study the 
351 mechanisms how PRRs distinguish foreign and endogenous RNAs.        
352 Besides in vitro-synthesized RNAs as foreign RNA mimics, it is also important to 
353 study how natural viral RNAs activate (or suppress) innate immune responses during 
354 viral infections. It is well known that several types of viral RNAs that are generated 
355 during virus infection are capable of inducing innate immune responses via different 
356 signaling pathways. These RNA molecules include viral genomic RNAs, viral RNA 
18
357 intermediates and small viral RNAs generated during virus transcription and 
358 replication [25,66,68,78-81]. Specifically, small viral RNAs generated during virus 
359 infection have an essential role in viral life cycle. Several studies have demonstrated 
360 that during flavivirus, such as West Nile virus (WNV) infection, an abundant pool of 
361 small RNAs, with a size distribution of 0.3 to 0.5 kb, is produced. These noncoding 
362 subgenomic flavivirus RNAs (sfRNAs) are derived from the 3' untranslated region of 
363 the viral genome [82,83] and have several important functions during flavivirus 
364 infection [84], such as facilitating viral replication, viral pathogenicity [85], and viral 
365 evasion from type I interferon-mediated antiviral responses [86]. Furthermore, by 
366 using deep sequencing, Dr. Velthuis and his colleagues identified mini viral RNAs 
367 with the size range of 56–125 nt generated during influenza A virus infection, which 
368 can efficiently trigger IFN responses via the RIG-I pathway [87]. This result is 
369 consistent with our data showing that in vitro-synthesized small ssRNA and dsRNA 
370 molecules, with the length from 58 nt to 128 nt, have a better efficacy to induce IFN 
371 responses via the RIG-I pathway than longer RNAs [37].                         
372 Moreover, some viral RNA-protein complexes, such as vRNPs of influenza 
373 viruses, can also activate innate immune responses [26]. Therefore, it is very useful to 
374 separate different types of natural viral RNAs or produce viral RNA mimics to further 
375 study the mechanisms of innate immune responses activated during viral infections. 
376 For example, we produced or isolated several types of influenza viral RNAs, 
377 including total viral RNAs extracted from virus stock of influenza A virus, in 
378 vitro-synthesized genomic viral RNAs specific for each of the eight influenza A virus 
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379 segments, pooled viral genomic RNAs, and RNAs extracted from virus infected cells, 
380 and compared the ability of these RNAs to induce innate immune responses [88]. We 
381 found that most of these viral RNAs can induce IFN responses with similar efficiency, 
382 which indicates that the sequence of influenza viral RNA is not the key factor 
383 regulating the induction of innate immune responses (Fig. 6). Instead, RNA length 
384 and the structural modifications are essential in the ability of viral RNA to induce 
385 innate immunity. These factors include e.g. small viral RNAs generated during virus 
386 replication [89] and 5’end triphosphate groups of genomic viral RNAs [37]. Since the 
387 replication strategy of different virus groups may be very different and also the RNA 
388 structures produced in different viral infections may vary, it is extremely important to 
389 identify the RNA variety for different viral pathogens. This information will give us 
390 better understanding of the pathogenesis of different viral infections and will likely 
391 provide us opportunities for the development of RNA-based antiviral therapies. 
392
393 6. Concluding remarks 
394 In conclusion, viral RNAs and their structural variables have become more and more 
395 important for the study of host innate immune responses and as potential targets for 
396 RNA-based therapeutics against viral infections. Therefore, methods for producing, 
397 separating and identifying different types of viral RNAs are urgently needed. Besides 
398 methods described above to produce various viral RNAs or their RNA mimics, 
399 researchers have also started to use other methods to separate and identify extracted 
400 viral RNAs. These methods include e.g. RNA purification with steric exclusion 
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401 chromatography [90] and RNA deep sequencing methodology which allows 
402 identification of different viral genomic and small RNAs [91,92]. For instance, Dr. 
403 Russell and his colleague set up a new approach by using single-cell virus sequencing 
404 to determine the sequences in single cells infected by viruses [93]. However, the 
405 development of efficient methods to identify the variety of RNA structures is still in 
406 its early stage. But when more and more novel methods are applied for identifying 
407 different RNA structures, we will definitely have a broader view of the mechanism 
408 how foreign RNA is recognized and discriminated by the host innate immune system.  
409
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667 Figure 1. RNA classification. RNAs can be divided into endogenous RNAs and 
668 foreign RNAs such as RNAs delivered or synthesized during viral infections in the 
669 cells (dark green ellipse). Endogenous RNAs are transcribed from different DNA 
670 sequences (orange and yellow chimeric rectangle) in the nucleus (dotted green ellipse) 
671 and are classified into two groups: coding RNAs, which are first transcribed to 
672 pre-mRNAs (orange and yellow chimeric serrated rectangle) and are then processed 
673 into mRNAs (orange serrated rectangle); non-coding RNAs (ncRNAs, yellow serrated 
674 rectangle), which are not translated into proteins and they can be divided into 
675 housekeeping ncRNAs and regulatory ncRNAs. Housekeeping ncRNAs include 
676 transfer RNA (tRNA), ribosomal RNA, small nuclear RNA (snRNA) and small 
677 nucleolar RNA (snoRNA). Regulatory ncRNAs consist of long ncRNAs and short 
678 ncRNAs. Long ncRNAs contain e.g. circle RNA (ciRNA), long intergenic ncRNA 
679 (lincRNA), and pseudogene transcripts. Short ncRNAs include micro RNA (miRNA), 
680 piwi-interacting RNA (piRNA) and small interfering RNA (siRNA).  
681 Different types of RNAs can be released into cells during viral infections, such as 
682 viral genomic ssRNAs with 5’end monophosphate or triphosphate, cap structure or 
683 protein tags, small viral RNA (small vRNA) and dsRNA intermediates during virus 
684 replication, and specific viral RNA-protein structures for instance vRNPs found in 
685 influenza viruses or influenza virus-infected cells.
686
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687 Figure 2. Enzymatic generation of different types of RNAs. (A) Enzymatic generation 
688 of different ssRNA or dsRNA molecules with different structures. A designed DNA 
689 sequence (rose red rectangle) is generated by PCR using forward primer harboring the 
690 promoter sequence for T7 DNA-dependent RNA polymerase at the 5'end. T7 RNA 
691 transcription is then performed to yield ssRNA (dark blue wavy lines) with different 
692 lengths (short ssRNAs <200nt, medium size ssRNAs 200−1000nt, and long 
693 ssRNAs >1000nt) using various DNA sequences as templates (top panel). A set of 
694 dsRNAs with the same lengths (light blue wavy lines) is generated from the ssRNA 
695 template by primer-independent phi6 RdRp-catalyzed RNA replication. Synthesized 
696 ssRNA and dsRNA molecules can be modified by cIAP enzyme to remove 5’end 
697 triphosphate group, or RNA molecules can be further modified e.g. by RNA capping. 
698 (B) Enzymatic production of DsiRNA swarm. Several target DNA sequences are 
699 chosen and chimeric DNA template is designed, followed by T7 RNA transcription to 
700 produce ssRNA with a chimeric target sequence (orange wavy line). DsRNA is 
701 generated from ssRNA template by primer-independent phi6 RdRp-catalyzed 
702 replication (light rose red wavy lines). The generated dsRNA is purified and cleaved 
703 by a Dicer enzyme to generate an siRNA swarm (green small wavy lines) containing 
704 different siRNAs targeting multiple RNA regions. Digestion with human Dicer 
705 produces canonical 21-nt long siRNA molecules while Giardia intestinalis Dicer can 
706 be used to produced 27-nt long siRNA. After introduction into human cell the 27-nt 
707 long siRNA is further processed by the endogenous Dicer and therefore such siRNA 
708 is called as Dicer-substrate siRNA (DsiRNA). 
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709
710 Figure 3. Broad-spectrum inhibition of influenza A virus replication in human moDCs 
711 by pre-transfection with an influenza A virus-specific DsiRNA swarm. Human 
712 moDCs from four different blood donors were separately pre-transfected with control 
713 or negative siRNAs (neg siRNA) or eGFP DsiRNA or specific DsiRNA swarm 
714 against influenza A virus (cIAV DsiRNA) (10 nM) for 21h. Cells were subsequently 
715 infected by indicated influenza A virus strains (H5N1, H7N9, H3N2 and H1N1) at 
716 multiplicity of infection 1. A. 24 h p.i. cells from different blood donors were pooled 
717 and the M1 RNA expression of influenza A virus was determined by quantitative 
718 reverse transcription PCR (qRT-PCR) from isolated total cellular RNA samples. The 
719 values were normalized against β-ACTIN gene–specific mRNA, and relative M1 
720 RNA levels of influenza A virus were calculated by the ΔΔCt method using untreated 
721 cells as a calibrator. The means (±SD) of 3 parallel analyses are shown. Data are 
722 representative of 3 individual experiments. The statistical significance is indicated as 
723 (*) P<0.05 or (**) P<0.01 against samples of non-siRNA transfected cells (boxed 
724 bars). Viral M1 RNA expression (top) is shown in relation to the immunoblot analysis 
725 of viral PB1, NP, M1, NS1 proteins in siRNA/DsiRNA transfected moDCs infected 
726 with the indicated strains of influenza A viruses. Human β-ACTIN protein levels were 
727 analyzed as a control. Cells were collected at 24 h p.i., and whole cell lysates were 
728 prepared. Cellular proteins (30 μg/lane) were separated by electrophoresis in 10% 
729 SDS-polyacryl amide gel, followed by Western blot analysis with the indicated 
730 antibodies. One representative experiment of three independent experiments is shown. 
32
731 The figure is adapted from a figure in reference 43.
732
733 Figure 4. RNA transfection efficacy in primary human monocyte-derived dendritic 
734 cells (moDCs) and cell viability of moDCs after RNA transfection. Human primary 
735 monocytes obtained from four different blood donors were differentiated into moDCs 
736 in 12-well plates. Then cells were un-transfected (control) or separately transfected 
737 with BLOCK-iT™ Alexa Fluor® Red Fluorescent Control (50nM or 25nM) using 
738 indicated transfection reagents, including lipofectamine 3000 (LF3000), siPORT, 
739 lipofectamine RNAiMAX (LF RNAiMAX), TransIT-siQuest (siQuest), TransIT-TKO 
740 (TKO) and DharmaFECT1 for 24h. Cells were washed with 0.5% bovine serum 
741 albumin in phosphate-buffered saline and collected and stained with propidium iodide 
742 (PI) for cell viability analysis after transfection. The samples were analyzed with a 
743 FACSCanto II (BD) device using FACSDiva software to analyse transfection efficacy 
744 as Alexa Fluor expression and the rate of cell death as PI positivity.  
745
746 Figure 5. Activation of innate immune responses with different-sized RNA molecules. 
747 Mouse wild-type (wt) cells (expressing RIG-I and MDA5), RIG-I knock-out (KO) 
748 cells (RIG-I -/-, lack of expression of RIG-I), MDA5 KO cells (MDA5 -/-, lack of 
749 expression of MDA5), and RIG-I/MDA5 double-KO cells (RIG-I -/-, MDA5 -/- 
750 double KO, lack of expression of both RIG-I and MDA5) (in 12-well plates; 5 × 105 
751 cells/well) were mock transfected (control) or transfected with in vitro-produced 
752 different size ssRNAs or dsRNAs (100 ng/ml). After 24 h of incubation, cells were 
33
753 collected for RNA isolation and quantitative RT-PCR analysis. The values of 
754 RT-PCR analyses were normalized against β-actin gene-specific mRNA, and the 
755 relative Ifn-β mRNA level was calculated by the ΔΔCT method using untreated 
756 control cells as a calibrator.   
757
758 Figure 6. Analysis of activation of innate immune responses in human moDCs by 
759 synthetic and natural influenza A virus-specific RNAs. MoDCs from four different 
760 blood donors were mock transfected (control) or separately transfected with indicated 
761 RNAs (100 ng/ml), including low molecular weight poly I:C, a synthetic analog of 
762 dsRNA, viral RNA extracted from influenza A virus stock (vRNA), enzymatically 
763 produced ssRNAs specific for each of the 8 genomic segments of influenza A virus 
764 (ssRNA1 to ssRNA8), pooled ssRNAs (from ssRNA1 to ssRNA8), and RNAs 
765 extracted from influenza A virus-infected cells. Influenza A virus-specific RNAs were 
766 produced as previously described [88]. After 24 h of incubation, cells were collected 
767 for RNA isolation. Relative expression of type III interferon, IFN-λ1 mRNA, was 
768 measured by quantitative RT-PCR. IFN-λ1 mRNA values were normalized against 
769 18S rRNA, and relative expression levels were calculated with the ΔΔCt method 




773 5. Different ssRNA and dsRNA can be produced in vitro using bacteriophage T7 
774 DNA-dependent RNA polymerase and phi6 RNA-dependent RNA polymerase, 
775 respectively. 
776 6. RNA can be delivered into cells by various transfection methods, however, the 
777 timing, amount, purification and the reagents for RNA transfection should be 
778 carefully considered.
779 7. Produced ssRNA and dsRNA can be applied e.g. in studying host innate immune 
780 responses, demonstrating that RIG-I preferentially recognizes short 
781 dsRNAs/ssRNAs bearing 5’end triphosphate group, while MDA5 recognizes 
782 longer dsRNA molecules. 
783 8. This in vitro RNA synthesis system can produce DsiRNA swarms with basically 
784 any virus (or microbe) specificity for protecting host cells from virus infection.
785
